Seattle-based startup HDT Bio received nearly $1.8M from the U.S. Army to develop a nasal spray designed to treat a variety of respiratory diseases.
The nasal spray will utilize the company’s technology that involves a proprietary nanoparticle that delivers an attached RNA into cells. The same approach was recently approved for a COVID-19 RNA vaccine in India.
HDT Bio plans to commence safety and potency studies and anticipates beginning clinical trials in 2025.
“We hope to address not only disease progression, but transmission,” said HDT Bio Chief Operating Officer Christopher Pirie.